Eiger BioPharmaceuticals, Inc. (EIGR) Reaches $9.45 After 6.00% Up Move; Eleven Biotherapeutics (EBIO) Has 2.25 Sentiment

March 13, 2018 - By Vivian Park

The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) is a huge mover today! The stock increased 5.59% or $0.5 during the last trading session, reaching $9.45. About 57,308 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has declined 64.64% since March 13, 2017 and is downtrending. It has underperformed by 81.34% the S&P500.The move comes after 7 months positive chart setup for the $99.38 million company. It was reported on Mar, 13 by Barchart.com. We have $10.02 PT which if reached, will make NASDAQ:EIGR worth $5.96 million more.

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics . The company has market cap of $36.93 million. It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. It currently has negative earnings. The companyÂ’s lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.

The stock increased 3.57% or $0.04 during the last trading session, reaching $1.16. About 1.12M shares traded. Eleven Biotherapeutics, Inc. (EBIO) has risen 30.97% since March 13, 2017 and is uptrending. It has outperformed by 14.27% the S&P500.

Bank Of New York Mellon Corp holds 0% of its portfolio in Eleven Biotherapeutics, Inc. for 40,358 shares. Barclays Plc owns 76 shares or 0% of their US portfolio. Moreover, Blackrock Inc. has 0% invested in the company for 443,691 shares. The Texas-based Bridgeway Capital Management Inc has invested 0% in the stock. Citadel Advisors Llc, a Illinois-based fund reported 22,747 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: